College of Medicine, The Pennsylvania State University, Hershey, Pennsylvania, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Penn State Health-Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Liver Int. 2024 Feb;44(2):532-540. doi: 10.1111/liv.15769. Epub 2023 Nov 28.
Exercise training is recommended for all patients with metabolic dysfunction-associated steatotic liver disease and may reverse liver fibrosis. Whether exercise training improves liver fibrosis without body weight loss remains controversial. We further investigated this relationship using serum biomarkers of liver fibroinflammation in a post hoc analysis of an exercise trial where patients did not lose significant body weight.
In the NASHFit trial, patients with metabolic dysfunction-associated steatohepatitis were randomized to receive either moderate-intensity aerobic exercise training or standard clinical care for 20 weeks. Mediterranean-informed dietary counselling was provided to each group. Change in serum biomarkers was measured and compared between the two groups.
Exercise training led to improvement in serum biomarkers of liver fibroinflammation, including (1) ≥17 IU/L reduction in alanine aminotransferase (ALT) in 53% of individuals in the exercise training group compared to 13% in the standard clinical care group (p < 0.001; mean reduction 24% vs. 10% respectively) and (2) improvement in CK18 (-61 vs. +71 ng/mL, p = 0.040). ALT improvement ≥17 IU/L was correlated with ≥30% relative reduction in magnetic resonance imaging-measured liver fat and PNPLA3 genotype.
Exercise training improves multiple serum biomarkers of liver fibroinflammation at clinically significant thresholds of response without body weight loss. This study provides further evidence that exercise training should be viewed as a weight-neutral intervention for which response to intervention can be readily monitored with widely available non-invasive biomarkers that can be applied at the population level.
运动训练推荐用于所有代谢功能障碍相关脂肪性肝病患者,且可能逆转肝纤维化。运动训练是否在不减轻体重的情况下改善肝纤维化仍存在争议。我们通过对一项运动试验的事后分析,使用肝纤维化炎症的血清生物标志物进一步研究了这一关系,该试验中患者的体重没有明显减轻。
在 NASHFit 试验中,代谢功能障碍相关脂肪性肝炎患者被随机分配接受中等强度有氧运动训练或标准临床护理 20 周。为每组提供地中海饮食咨询。比较两组之间血清生物标志物的变化。
运动训练导致肝纤维化炎症的血清生物标志物改善,包括(1)运动训练组 53%的个体 ALT 降低≥17IU/L,而标准临床护理组为 13%(p<0.001;分别平均降低 24%和 10%)和(2)CK18 改善(-61 比+71ng/ml,p=0.040)。ALT 改善≥17IU/L 与磁共振成像测量的肝脂肪相对减少≥30%和 PNPLA3 基因型相关。
运动训练在不减轻体重的情况下改善多种肝纤维化炎症的血清生物标志物,达到临床显著反应阈值。本研究进一步证明,运动训练应被视为一种体重中性干预措施,其干预反应可通过广泛应用的非侵入性生物标志物进行监测,这些标志物可在人群水平上应用。